Imaging of Coronary Plaques in Participants Treated With Evolocumab

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-01-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: therapydlmyocardialcoronarycarcinoma
  Phrases that lowered it: screeninginvestigatoreffect ofthe effectopinion
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.0% (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 15.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 1.1% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 57 (lowers risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 518 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 54821 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 27913 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound NCT01813422 · started 2013 · scored riskier than 79% of active trials completed
• Effect of Evolocumab on Coronary Atherosclerosis NCT03689946 · started 2019 · scored riskier than 89% of active trials completed
• MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial NCT02678923 · started 2015 · scored riskier than 92% of active trials completed
• EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) NCT03287609 · started 2018 · scored riskier than 70% of active trials completed
• Vascular Effects of Alirocumab in Acute MI-Patients NCT03067844 · started 2017 · scored riskier than 72% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.